ClinicalThought

Share

Program Content

Activities

  • Recent Progress in AML
    Why I Am Optimistic About Recent Progress in AML
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 22, 2016

    Expires: March 21, 2017

  • MRD Assessment in ALL
    Optimizing MRD Assessment in ALL: Why, How, and When
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 22, 2016

    Expires: April 21, 2017

  • Novel Immunotherapies in ALL
    Addressing Financial Challenges With Use of New Immunotherapies for Relapsed ALL
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 19, 2016

    Expires: May 18, 2017

  • CD123 in AML
    Targeting CD123 in AML
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 28, 2016

    Expires: June 27, 2017

  • Improving Prospects in AML and ALL
    Major Discoveries and the Prospect of Improved Patient Survival in AML and ALL
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 26, 2016

    Expires: July 25, 2017

  • Immunotherapy in ALL
    How I Interpret Clinical Trial Results to Choose Salvage Immunotherapies for Adult Patients With B-Precursor ALL
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 01, 2016

    Expires: August 31, 2017

Faculty

cover img faculity

Dan Douer, MD

Associate Professor of Medicine-Hematology
University of Southern California/Norris
Comprehensive Cancer Center and Hospital
Los Angeles, California

cover img faculity

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

cover img faculity

Jonathan Webster, MD

Fellow
Division of Hematologic Malignancies
Department of Oncology
Johns Hopkins University
Baltimore, Maryland

Provided by

ProCE Banner

Supporters

Amgen, Inc.